IMPORTANCE Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal genetic arrhythmia syndrome characterized by polymorphic ventricular tachycardia with physical or emotional stress, for which current therapy with β-blockers is incompletely effective. Flecainide acetate directly suppresses sarcoplasmic reticulum calcium release-the cellular mechanism responsible for triggering ventricular arrhythmias in CPVT-but has never been assessed prospectively.
C atecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic arrhythmia syndrome, is characterized by polymorphic ventricular tachycardia with physical or emotional stress in patients with a structurally normal heart.
1 It can be a particularly lethal channelopathy, resulting in symptom onset during childhood and cardiac arrest as a frequent presentation. 2 Mutations in the genes encoding the cardiac ryanodine receptor 2 calcium release channel (RYR2 [OMIM 180902]) or cardiac calsequestrin (CASQ2 [OMIM 114251] ) are implicated in approximately 60% of cases. 3, 4 These proteins regulate intracellular calcium homeostasis in myocytes, and disruptions resulting in excessive sarcoplasmic reticulum calcium release are arrhythmogenic. 5 The recommended first-line therapy for CPVT consists of β-blockers, 6 but recurrent events are common despite β-blocker therapy, especially in children, and rates of near-fatal and fatal events remain unacceptably high. 7 The implantable cardioverter defibrillator (ICD) can be useful in patients at high risk of CPVT events, but ICD shocks can trigger catecholamine release, resulting in arrhythmic storm, multiple shocks, and death. 8, 9 Left cardiac sympathetic denervation is a promising option for severely affected patients with syncope despite optimal medical therapy, but it is limited to specialized centers. 10, 11 To date, randomized clinical trials have not been performed in CPVT and are exceptional in cardiac channelopathy research, as stated in the most recent international expert consensus statement: "randomized and/or blinded studies do not exist in this field".
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Flecainide acetate is a class IC antiarrhythmic drug approved by the US Food and Drug Administration for use in children and adults for the prevention of documented ventricular arrhythmias judged by the physician to be life-threatening. In 2009, Watanabe et al 12 reported the unexpected finding that flecainide showed remarkable efficacy in suppressing sarcoplasmic reticulum calcium release, the cellular mechanism responsible for triggering ventricular ectopy in CPVT. Flecainide also inhibits delayed afterdepolarization-mediated triggered activity due to sodium channel block, an additional potential mechanism for efficacy in CPVT. 13 Flecainide prevented catecholamine-induced ventricular arrhythmias in a well-established mouse model of CPVT and was highly efficacious in 2 severely affected patients with drugrefractory CPVT. 12 In a retrospective open-label therapeutic trial, flecainide was associated with reduced exercise-induced arrhythmias in 22 of 29 patients with CPVT compared with a β-blocker alone. 14 Reduction of exercise-induced arrhythmias is a clinically relevant outcome because persistence of ventricular arrhythmias in the form of couplets or nonsustained ventricular tachycardia (NSVT) on exercise testing has been associated with subsequent cardiac events in CPVT. 15 To study the efficacy of flecainide added to conventional treatment with maximally tolerated β-blockers in the treatment of CPVT, we conducted a single-blind, placebocontrolled, randomized clinical crossover trial.
Methods

Trial Design and Protocol Change After Enrollment Started
We conducted a single-blind, multicenter, placebo-controlled, randomized clinical crossover study at 10 centers in the United States (Vanderbilt University Medical Center, Nashville, Ten- December 19, 2011 , through December 29, 2015 , with a midtrial change in protocol and primary outcome due to low enrollment. The study was approved by the institutional review board at each participating center. All patients 18 years or older provided written informed consent; those younger than 18 years provided assent, and a parent or guardian provided written informed consent. The initial study design was a single-blind (blinded participants) randomized crossover study in which each participant received flecainide or placebo (treatment A) for 18 months and, after a 1-week washout, crossed over to placebo or flecainide (treatment B) for 18 months. Exercise treadmill tests were performed at enrollment (baseline, using β-blocker therapy only), 3 months after treatment A, and 3 months after crossover to treatment B. The primary end point was VT or appropriate ICD therapy, and the secondary end point was the degree of ventricular arrhythmias induced on exercise testing. Adequate power for the primary end point required enrolling 60 subjects. In June 2015, after only 14 of the desired 60 participants were enrolled, and with approval from the funding source and the data and safety monitoring board (DSMB), we modified the study protocol to evaluate only the secondary end point (ventricular arrhythmias on exercise testing). At that point, participants who had completed the treatment A exercise test crossed over without the 18-month treatment duration. Similarly, participants discontinued treatment B after the 3-month exercise test was complete. The initial protocol, modified protocol, and statistical analysis plans are available in Supplement 1.
Trial Participants
We recruited children and adults with a clinical diagnosis of CPVT and a functioning ICD in place from the 10 US centers. Inclusion criteria were a clinical diagnosis of CPVT based on reproducible polymorphic/bidirectional VT with exercise or ventricular ectopy during exercise testing, with a putative pathogenic RYR2 (heterozygous) or CASQ2 (homozygous) mutation; a functioning ICD in place; and a stable dosage of standard therapy defined as the maximal tolerated dosage of β-blocker. The dosage and choice of β-blocker were determined by the patients' physicians before trial entry and remained unchanged throughout the conduct of the trial. Patients were excluded if they were pregnant or planning to become pregnant during the study period, were younger than 5 years, were unable to perform treadmill exercise, had significant structural heart disease, were taking amiodarone hydrochloride, or had a known hypersensitivity to flecainide. Patients using flecainide before enrollment were eligible for the trial; these participants discontinued flecainide therapy at least 1 week before their baseline assessment. Documentation of the clinical diagnosis of CPVT (electrocardiographic [ECG] recordings of ventricular ectopy during exercise, genetic test reports) and absence of structural heart disease (cardiac imaging reports) was reviewed and confirmed by the coordinating center before randomization. Female patients had a negative pregnancy test result at the first study visit and at the crossover visit. The race and ethnicity of each patient were recorded, in accordance with US National Institutes of Health policy and definitions.
Randomization and Blinding
Randomization of treatment order was performed at the coordinating center, and assignments were distributed to the participating sites at the time of enrollment. Participants were randomized in permuted blocks of 4. The study drug, flecainide acetate, was administered every 12 hours, with a starting dose of 100 mg/d (50 mg every 12 hours) and a maximum dose of 400 mg/d. Study drug and placebo were provided by a central pharmacy (US Compounding) and mailed directly to enrolled participants; flecainide and placebo were similar in appearance. Investigators were aware of treatment assignment, but participants were blinded.
Study Procedures
After enrollment (and a 1-week washout for participants who previously used flecainide), patients underwent a baseline exercise test during standard therapy with β-blocker alone. Patients then initiated treatment A (flecainide or placebo) in a blinded fashion. After 1 week, a trough flecainide level and ECG were obtained. For patients randomized to flecainide, the target serum level was 0.50 to 0.80 μg/mL. Patients with levels of less than 0.35 μg/mL had the dose doubled, and those with levels of 0.35 to 0.50 μg/mL increased the dosage by 50%, unless the maximum dosage had been achieved. Patients requiring a dose adjustment (and randomly chosen participants in the placebo arm) had a second serum sample and ECG obtained at 1 month. Any additional dose adjustments were made before the 3-month visit, with all patients taking their trough level-adjusted dosage for at least 20 consecutive days before the exercise test. Serum levels were obtained locally, and dosage adjustments were made by the coordinating center and central pharmacy after confirmation with the enrolling site investigator (P.J.K., J.P.M., M.C., S.G.P., N.J.K., P.S.R., A.S.B., E.S.K., D.L.F., E.V.S., S.P.E., R.J.K., M.P.C., and M.V.D.) that no adverse effects or significant widening of the QRS complex duration on ECG occurred. The dosage escalation continued until the trough flecainide level was greater than 0.50 μg/mL, the QRS width was greater than 120 milliseconds or prolonged by more than 50 milliseconds of the baseline QRS, or the maximum dosage was achieved. Adherence with the flecainide regimen was confirmed with serum levels obtained on the day of each exercise test.
Participants underwent initial exercise treadmill testing at baseline while receiving β-blockers only. After 3 months of treatment A, participants underwent exercise treadmill testing (exercise test A) and had a serum sample obtained for measurement of the flecainide level. Participants then discontinued treatment A, and after 1 week of standard therapy alone, started treatment B. Determination of flecainide dosage and levels was performed as described above. After 3 months of treatment B, another exercise test (exercise test B) was performed and a serum flecainide level was measured. Treatment B was discontinued after exercise test B, and the patient's participation in the study was complete. Participants were then unblinded, and the decision to continue flecainide therapy was left to the discretion of the treating physician.
Trial Oversight
The US Food and Drug Administration reviewed the protocol and concluded that the study met all the requirements for exemption from Investigational New Drug regulations. The DSMB met before enrollment and then biannually through the conclusion of the trial. Per National Heart, Lung and Blood Institute (NHLBI) policy (updated in December 2014), NHLBI program staff participated as nonvoting members in DSMB meetings beginning in 2015.
End Points and Statistical Analysis
The original primary end point was VT or appropriate ICD therapy. In June 2015, after the protocol change, the primary end point was reduction in ventricular ectopy at the exercise test with comparison of flecainide and placebo. Exercise tests were analyzed and scored as previously described 14, 16 on an ordinal scale of worst ventricular arrhythmia observed in which 0 indicates no ventricular ectopy; 1, isolated premature ventricular contractions (<10 per minute); 2, premature ventricular contractions in a bigeminal pattern (>10 per minute); 3, ventricular couplets (2 consecutive beats); and 4, nonsustained VT (≥3 consecutive beats). In addition, the following exercise variables were compared: resting heart rate, peak sinus heart rate, exercise time, maximal workload achieved, and maximal number of ventricular ectopic beats during the worst 10-second period of exercise. Analysis of exercise tests was performed with the investigators blinded to treatment assignment. Throughout the trial, the incidence and severity of all adverse events were recorded. The National Institutes of Health Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) was used to grade severity of adverse events. Adverse events with CTCAE grade 3 or higher were considered to be serious. The DSMB regularly reviewed adverse event data. Adverse events, serious adverse events, and likely drug-related adverse events were compared between the flecainide and placebo arms. Data are reported as medians and interquartile ranges or as numbers and percentages. All comparisons were evaluated using Wilcoxon signed rank test with continuity correction, with P < .05 indicating statistical significance. Data were analyzed using R software (version 3.2.2; https://www.r-project.org/). Interim analysis was not performed.
Results
Trial Population
A total of 14 participants (7 males and 7 females) were randomized. One participant randomized to placebo for treatment A withdrew from the study 3 months after the treatment A exercise test owing to pregnancy (she had a negative pregnancy test result at enrollment). This participant was excluded from the study cohort because she did not receive flecainide during the trial. One participant randomized to flecainide for treatment A withdrew before treatment B (placebo) exercise test. This participant was included in the study cohort but is excluded from the primary paired analysis comparing flecainide and placebo (Figure 1) . Baseline characteristics of the study cohort (n = 13) are listed in Table 1 . The cohort was young (median age, 16 years [interquartile range, 15.0-22.5 years] ) and predominantly white and non-Hispanic. Putative pathogenic mutations were present in RYR2 in 10 patients and CASQ2 in 1; 2 patients had negative genetic findings. Seven patients had a history of aborted cardiac arrest; in 4, it was their presenting symptom. All patients were using β-blockers, primarily nadolol, at maximally tolerated dosages. At the time of the protocol change, 3 participants had completed the full original protocol. Nine additional participants completed the original protocol timeline through the treatment B exercise test and discontinued treatment B a few months earlier than originally planned. Only 1 participant had not already crossed over to treatment B when the protocol change was made. That participant crossed over after 9 months of treatment A and then received treatment B for 3 months, followed by the treatment B exercise test.
Original Primary Outcome Before Protocol Change
Only 3 ICD therapies for VT (the originally intended primary outcome) were observed in 2 participants. One participant received an appropriate shock during each arm of the study, after 108 days in the flecainide arm and after 194 days in the placebo arm. At exercise testing, this participant had NSVT at baseline, bigeminy during flecainide treatment, and NSVT during placebo treatment. One participant randomized to placebo first had no ICD shocks during 18 months of the placebo treatment and had an appropriate shock after 284 days of flecainide treatment. At exercise testing, this participant had couplets at baseline, NSVT during placebo treatment, and bigeminy during flecainide treatment. In all 3 instances of ICD shocks, the participants did not seek medical attention until several weeks later, precluding assessment of compliance with a flecainide level at the time of ICD shock. Aside from these 3 episodes treated with an ICD shock, no episodes of sustained VT or inappropriate ICD shocks and no deaths occurred during the trial.
Primary Outcomes After Protocol Change
The median baseline exercise test score was 3 (range, 0-4), with 9 participants experiencing ventricular couplets or nonsustained VT despite maximally tolerated β-blocker therapy. in the 12 patients with data available and compared with β-blocker therapy alone (baseline; P = .005) in the 13 patients with data available (Table 2 and Figure 2 ). Two patients with NSVT with placebo had persistent bigeminy with flecainide (with levels of 0.44 and 0.48 μg/mL), and complete suppression was observed in 11 of 13 (85%). We found no significant difference between the baseline (median, 3.0; range, 0-4) and placebo (median, 2.5; range, 0-4) exercise scores (P = .70). All flecainide levels on the day of the placebo exercise test were less than 0.10 μg/mL. The maximal number of ectopic beats during the worst 10 seconds was also significantly reduced by flecainide (0 [range, 0-11] vs 10 [range, 0-17] by placebo; P = .009) in the 12 patients with data available. We found no difference in the maximal number of ectopic beats during 10 seconds between baseline and placebo (13 [range, 0-17] vs 10 [range, 0-17]; P = .39). Total exercise time, maximal workload achieved, and resting heart rate were not significantly affected by flecainide, but peak sinus rate was lower compared with the baseline and placebo exercise tests (eTable 1 in Supplement 2).
Adverse Events
Overall adverse events were frequent and did not differ significantly between the flecainide and placebo arms (mean, A, Change in arrhythmia score for each patient between the placebo and flecainide acetate arms for the 12 patients with available data (P = .008). B, Change in arrhythmia score for each patient between baseline (β-blocker only) vs flecainide arm for the 13 patients with available data (P = .005).
C, Change in arrhythmia score for each patient between baseline (β-blocker only) vs placebo arm for the 12 patients with available data (P = .70). NSVT indicates nonsustained ventricular tachycardia; PVC, premature ventricular contractions. 1.6 events per patient with flecainide vs 1.1 events per patient with placebo; P = .22). Serious adverse events occurred with similar frequency between flecainide (2 events in 2 patients) and placebo (4 events in 2 patients) (P = .42), and none were likely to have been related to the study drug, as judged by the study team and DSMB (eTable 2i nSupplement 2). Adverse events likely related to the study drug were more common with flecainide (P = .04) and included blurry vision in 4 cases and 1 case each of lightheadedness and fatigue. One case of diarrhea occurred during placebo treatment.
Discussion
This randomized placebo-controlled crossover study demonstrated that flecainide added to β-blocker therapy is superior to maximally tolerated β-blocker therapy alone in reducing exercise-induced ventricular arrhythmias in patients with CPVT. in partial responders, and 150 (60) mg in those with complete suppression. This finding is further supported by our finding that a median dosage of 300 mg/d was required to achieve target trough drug levels. One could speculate that chronotropic incompetence from combination therapy with β-blocker plus flecainide would result in lower levels of exertion during exercise and thus a lower arrhythmia score. However, maximal workload achieved during each exercise test did not differ significantly, suggesting similar levels of effort across the 3 exercise tests. Nadolol has recently been shown to be superior to β1-selective β-blockers in suppressing ventricular arrhythmias during exercise testing in CPVT. 19 The previous retrospective studies 14, 16, 18 investigating the efficacy of flecainide have included cohorts where nadolol use was infrequent (5 of 29, 4 of 12, and 0 of 10 patients), and β1-selective β-blockers were common in the 2 larger studies (19 of 29 and 6 of 12 patients). 14,16 Thus, in retrospect, many of those patients may not be receiving optimal β-blocker therapy for CPVT. Our cohort was predominantly treated with nadolol and at maximally tolerated dosages, but many were still at risk for cardiac events, as evidenced by couplets or NSVT on exercise testing. Our data demonstrate that flecainide prevents exercise-induced ventricular arrhythmias in those with significant ventricular ectopy despite optimal β-blocker therapy.
The care of patients with CPVT and other genetic arrhythmia syndromes is limited by the lack of a robust evidence base for nearly all therapies. In the most recent expert consensus statement on the diagnosis and management of inherited primary arrhythmia syndromes, 6 all recommendations are level of evidence C (expert opinion). On the basis of primarily the previous retrospective data, 14, 16 flecainide is now listed as a class IIA recommendation in addition to β-blockers in patients with CPVT who experience recurrent syncope or polymorphic/bidirectional VT while using β-blockers. Flecainide appears to have been rapidly adopted into clinical practice because a recent publication (the largest published series to date) reported flecainide use in 23% of patients with CPVT. 2 One of the challenges to enrollment in the present trial was the relatively widespread use of flecainide in patients with difficult to control CPVT. Some of these patients and their clinicians were unwilling to discontinue flecainide therapy and be randomized to placebo, again based on results of retrospective open-label studies.
We provided a higher level of evidence supporting flecainide use for treatment of CPVT and did not observe any proarrhythmia or worsening of ventricular arrhythmias during exercise. Overall and serious adverse events were no more frequent with flecainide compared with placebo. None of the serious adverse events (eTable 2 in Supplement 2)were related to study drug. Adverse events related to flecainide were mild.
Limitations
This study is limited by the small sample size, because we were unable to enroll enough patients to assess our originally intended primary end point (appropriate ICD therapies). Although with the statistically efficient crossover design we were adequately powered to detect a difference in exercise test scores, this outcome is still a surrogate. Study participants were blinded, but it was not possible to blind investigators, because flecainide use is apparent from QRS widening on the ECG. Reduction of exercise-induced arrhythmias is clinically relevant in the care of patients with CPVT 15 but may not have applicability in other conditions.
All study patents were receiving maximally tolerated dosages of β-blockers at baseline, mostly nadolol, but 3 were using β1-selective β-blockers. Recently published data suggest that nadolol is superior to β1-selective β-blockers for suppression of ventricular arrhythmias during exercise test-ing in CPVT. 19 These 3 patients in our study who received β1-selective β-blockers might have a lower exercise score at baseline and with placebo with nadolol. Because the data regarding nadolol's superiority in reducing exercise-induced arrhythmias was published after completion of this trial, we did not change the medication of the 3 patients using β1-selective β-blockers to nadolol during the study period. We also did not formally assess adequacy of β-blocker dosage, which was determined before trial entry by treating physicians and remained constant throughout the clinical trial. Because all patients were using β-blockers throughout the trial, we do not have any data supporting flecainide as monotherapy, which has been suggested for the rare patient who cannot tolerate any dose of β-blocker. 20 The protocol change could have had an effect on study participants that biased the results, although we cannot easily speculate in which direction the results would be biased.
Conclusions
This prospective placebo-controlled randomized clinical trial demonstrates that flecainide, dosed to therapeutic trough levels, is highly efficacious in reducing ventricular arrhythmias associated with exercise in patients with CPVT and persistent exercise-induced ectopy despite a maximally tolerated β-blocker dose. No serious adverse events or proarrhythmias were related to flecainide. Long-term follow-up studies are required to ensure that cardiac events are reduced by flecainide plus optimal β-blocker therapy.
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Role of the Funder/Sponsor: The funding source had no direct role in the initial design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a genetic arrhythmia syndrome characterized by frequent ventricular ectopy and polymorphic, classically bidirectional ventricular tachycardia with physical or emotional stress, which also carries a risk of ventricular fibrillation and sudden death, despite no structural heart abnormality. (Liu et al.) The disease is caused by mutations in the cardiac ryanodine receptor gene (RYR2) or cardiac calsequestrin gene (CASQ2). (Priori et al.;Postma et al.) Exercise can elicit ectopy or VT in the majority of CPVT patients. Treatment consists of beta-blockers and/or calcium channel blockers, but up to 30% of patients require implantable cardioverter-defibrillators (ICDs) due to recurrent symptoms on medical therapy (Priori et al.) .
Rationale and Specific Aims
Additional forms of therapy for CPVT are needed, as current medications are not completely effective in all patients. By studying mouse models of CPVT (CASQ null mice), we have observed beneficial effects of flecainide, a class IC sodium channel blocker. In a retrospective clinical study in patients with CPVT we have also shown improvement of ventricular ectopy on exercise tests when flecainide is added to standard therapy.
The Specific Aims of this protocol are:
1: to test the hypothesis that the addition of oral flecainide to standard therapy will reduce cardiac events, defined as either VT treated by ICD or cardiac death, compared to placebo plus standard therapy, in patients with CPVT.
2. to test the hypothesis that ventricular ectopy and/or VT on treadmill exercise test in patients with CPVT on standard therapy is reduced by flecainide, but not by placebo.
3. to test the hypothesis that reduction in ventricular ectopy on exercise test is associated with reduction in cardiac events.
This will be a single-blind (blinded subjects) randomized cross-over study, in which each patient will receive treatment A (flecainide or placebo) for 18 months and, after a 1 week wash-out, treatment B (placebo or flecainide). The event rate and time to event will be assessed during each treatment period. Any events that occur during treatment A will result in early crossover to treatment B after 1 week of wash-out. Any events during treatment B will result in the end of the study for that subject.
Animal Studies and Previous Human Studies
Since the causal association between stress and arrhythmic symptoms of CPVT was recognized, beta--blockers have been the mainstay of therapy. Moreover, since polymorphic VT is reproducibly induced with exercise in the majority of patients with CPVT, it is common practice to use repeated exercise testing to evaluate the efficacy of -blocker therapy. While beta-blockers are very effective for preventing exerciseinduced sustained polymorphic VT, the majority of patients with CPVT continue to have different degrees of ventricular ectopy during exercise despite maximally tolerated dosages. In addition, studies report high mortality rates and a high incidence of recurrent polymorphic VT despite beta-blocker therapy.
The addition of calcium channel blockers to beta-blockers was reported in 6 children with CPVT, with an improvement in exercise-induced ectopy in all, and a marked clinical improvement in 1 (reduction in ICD shocks). (Rosso et al.) Left cardiac sympathetic denervation has also been reported as an effective alternative in 5 patients when symptoms persist despite the maximum tolerable dose of -blocker. (Wilde et al., Collura et al.) Oral flecainide has also been reported to reduce ventricular tachycardia in another genetic arrhythmia syndrome, Andersen-Tawil syndrome (ATS). (Bokenkamp et al.) Two siblings with ATS who failed therapy with beta-blockers and calcium channel blockers had marked improvement with oral flecainide. ATS shares some features with CPVT, in that the characteristic bidirectional ventricular tachycardia (only seen in CPVT, ATS, and digoxin toxicity) is frequently observed, again with minimal symptoms, yet patients are at risk for ventricular fibrillation.
Recently, we discovered that the class 1C antiarrhythmic agent flecainide directly blocked RyR2 channels, prevented RyR2-mediated premature Ca 2+ release, and suppressed triggered beats in myocytes isolated from mouse hearts lacking calsequestrin, an animal model of CPVT. (Watanabe, et al.) waves that trigger CPVT in vivo. (Hilliard et al.) Flecainide also appeared to be effective during short-term treatment in two highly symptomatic CPVT patients.
Based on these animal studies, we have collaborated with international centers to perform am open-label, nonrandomized therapeutic trial of oral flecainide for patients with CPVT and persistent ventricular ectopy on exercise testing on standard therapy. In this trial, 86% of patients had improvement of ventricular ectopy on exercise, and there was no worsening of ectopy with flecainide added to standard therapy.
Inclusion/Exclusion Criteria
Inclusion criteria:
• 
Enrollment/Randomization
Patient Enrollment: The treating physicians at each center will identify potential subjects and present a brief overview of the study; if the subject (or his/her parent/legal guardian for patients < 18 years) is interested, an investigator will be contacted and will approach them. Informed consent will be obtained by the investigator after discussing the study in detail, including the voluntary nature of participation and notification the subject can withdraw at any time. Ample time for questions and answers will be allowed. The investigator will give the subject and his/her legal guardian the opportunity to take the consent home to think about it more, with the option to call or meet with the investigator to ask additional questions. If the subject and his/her parent/legal guardian agree to participate, the investigator will ask them to sign a written, informed consent and assent. A copy of the assent and consent will be given to the subject and his/her parent/legal guardian. Subjects who are < 18 years of age at the time of enrollment who turn 18 years of age during the study period will be re-consented after their 18 th birthday. Subjects who wish to participate in the clinical trial without providing a DNA sample will be allowed to do so.
Patients already on flecainide will have a serum level drawn. If the level is > 0.5 mcg/ml, his/her previous dose will be the final study dose (no up titration). If the level is < 0.5, the previous dose will be the starting dose and up titration will occur as below. All subjects on flecainide will discontinue it for 1 week prior to the baseline assessment, continuing on standard therapy alone.
Randomization Procedure: This will be a single-blind placebo-controlled randomized crossover study with 2 treatments: oral flecainide or oral placebo. Each enrolled patient will receive both treatments for 18 months, with a 1 week washout period between. The order of treatments will be randomized 1:1 across all centers.
Study Procedures
All patients enrolled in the study will undergo the following baseline assessment and data collection:
• Demographics (age, gender, race)
• Review of data confirming clinical diagnosis of CPVT (recordings of polymorphic VT, exercise tests, genetic tests). Required components include:
o Normal imaging study (echocardiogram or cardiac MRI) o No evidence of coronary ischemia on ECG or exercise testing, unless subsequent stress imaging study was not suggestive of ischemia o For subjects with no family history of CPVT nor a putative pathogenic RYR2 or CASQ2 mutation who were > 35 years of age at the time of initial presentation with polymorphic VT, a coronary angiogram demonstrating no coronary artery disease must be documented.
• Previous anti-arrhythmic treatments • Prior ECG and echocardiogram reports Randomization There will be a 50:50 randomization across all centers, with half the subjects randomized to flecainide then placebo, and half randomized to placebo then flecainide.
Patients previously on flecainide with a serum level > 0.5 mcg/ml will receive a study dose equal to their previous dose. Patients previously on flecainide with a serum level < 0.5 mcg/ml will receive a starting dose equal to their previous dose, with uptitration as below. For all subjects not previously on flecainide, the starting dose will be based on age and weight. Children < 12 years of age will be dosed 3 times per day (every 8 hours) and patients > 12 years of age will be dosed 2 times per day (every 12 hours), based on plasma elimination half-life (Perry et al.) For children < 12 years of age an oral suspension will be used, the starting dose will be 2 mg/kg/day and the maximum dose will be 8 mg/kg/day. For patients > 12 years of age the starting dose will be 100 mg per day (50 mg every 12 hours) and the maximum dose will be 300 mg/day. Study drugs will be prepared and distributed by a central investigational pharmacy; flecainide and placebo will be similar in appearance.
After enrollment (and after a 1 week washout for subjects previously on flecainide), patients will undergo a baseline exercise test on standard therapy (Exercise test 0). Subjects with baseline ECG or exercise test evidence of ischemia must be excluded, unless stress imaging studies are performed and are not suggestive of ischemia. Patients will then initiate treatment A (flecainide or placebo) in a blinded fashion. After 1 week, blood samples for DNA isolation and storage, and determination of a flecainide level will be drawn. Each time a serum sample is obtained for a flecainide level, and ECG will be obtained. For patients on flecainide, the target serum level will be 0.5-0.8 mcg/ml. Patients with levels < 0.35 mcg/ml will have the dose doubled, and those with levels between 0.35 and 0.5 will increase the dose by 50%, unless the maximum dose has been achieved. Patients requiring a dose adjustment (and an equal number of randomly chosen subjects on placebo) will have a second serum sample drawn at 1 month. Any further dose adjustments and serum samples will be made prior to the 3 month visit. Serum levels will be obtained locally and dose adjustments will be done by the central pharmacy, after confirmation with the treating physician that there are no side effects or significant QRS widening.
The dose escalation will continue until either: 1. The trough flecainide level is > 0.5 mcg/ml 2. The QRS width is > 120 ms or prolonged by > 50% of the baseline QRS 3. The maximum dose is achieved.
At 3 months, all subjects undergo a repeat exercise test (exercise test A) and a serum sample drawn for a flecainide level. After 18 months of treatment A, subjects will discontinue the study drug, and after 1 week of standard therapy alone, start treatment B. Determination of flecainide levels will be done as above. After 3 months of treatment B, another exercise test (exercise test B) will be performed. After 18 months of treatment B, the subject will be removed from the study.
Patients will be followed every 6 months or as clinically indicated for ICD interrogation. Patients who receive therapy (shock or anti-tachycardia pacing) from the ICD will be carefully assessed and the ICD data downloaded. Therapies will be categorized as "appropriate" if delivered for ventricular tachyarrhythmias, or "inappropriate" if delivered for other reasons. In the event of an appropriate ICD therapy, a serum sample will be drawn for a flecainide level. Subjects that have events during treatment A will discontinue treatment A, start the 1 week washout period, and crossover to treatment B. Subjects with events during treatment B will be removed from the study and unblinded. Further treatment will be determined by the treating physician.
The primary endpoint will be cardiac event defined as appropriate ICD therapy (shock or anti-tachycardia pacing for VT) or death.
Secondary endpoints include reduction in ventricular ectopy at exercise test compared to baseline during treatment with flecainide but not placebo.
Exercise tests will be scored using the following scale:
Exercise test scoring system: 0= no ventricular ectopy 1=PVC's, < 1 in 2 beats, and < 10/min 2= PVC's in bigeminal pattern or > 10/minute 3= ventricular couplets 4= nonsustained VT (3 or more consecutive beats)
Reporting of Adverse Events or Unanticipated Problems involving Risk to Participants or Others
Any adverse events (AEs) will be recorded on the adverse event form (see attached) and sent to the Data Coordinating Center within 72 hours of the event. AEs will be reported to the IRB according to the IRB policies and procedures. The data coordinating center will notify the DSMB of any major adverse events. Any unanticipated problems involving risk to the participants or others will be discussed with the PI and DSMB.
Administration of flecainide is associated with the potential for serious side effects. In our preliminary studies, 8% of CPVT patients were unable to take flecainide due to bradycardia or fatigue and dizziness. Patients who discontinue the study drug (flecainide or placebo) due to side-effects will continue to be followed, with an intent-totreat analysis. Adverse events related to the administration of flecainide will be reported. All unanticipated problems/events such as breach of confidentiality will be reported.
Serious Adverse Events (SAEs) will have to be reported according to the following special procedure:
The occurrence of serious adverse events will be reported to the Investigator by telephone or fax; they must be reported to him/her within 24 hours after becoming aware of their occurrence. The Investigator will report SAEs to the Vanderbilt Institutional Review Board per policy.
Study Withdrawal/Discontinuation
Subjects may withdraw from the study at any time. Subjects will be unblinded at the time of withdrawal.
Statistical Considerations Sample Size Estimation and Power Analysis
The primary endpoint of this randomized controlled 2x2 cross-over trial will be cardiac event defined as appropriate ICD therapy (shock or anti-tachycardia pacing for VT) or death.
The objective is to demonstrate decreased event rate in patients treated with flecainide in addition to standard therapy compared to patients treated with standard therapy plus placebo. Previous studies of CPVT patients with ICD's reveal an event rate ranging from 50% over 20 months (Priori et al) to 25% over 3.9 years (Hayashi et al). This wide range results in an estimated event rate during 18 months of treatment with placebo plus standard therapy between 10 and 45%. In our small series of patients receiving open-label flecainide, we observed 1 event in 23 patients (4%), which was likely due to noncompliance. The event rate of the control group is expected to be 15% based on the above data. The sample size estimation was carried out using the Pearson chi-square test for paired proportions. With a sample size of 55, the study will have 80% power to detect a 10% difference in the primary endpoint with a two-sided test at 5% significance level. To compensate for reduced power caused by the noncompliance (the anticipated dropout rate over 36 months is 8% based on our pilot data), 60 patients will be enrolled.
Statistical Analysis Plan
Descriptive statistics, including means, standard deviations, and ranges for continuous variables, as well as percentages and frequencies for categorical variables, will be provided to describe the study sample. Pearson chi-square test or Fisher's exact test will be used to assess the categorical variables. Differences between group means for continuous variables will be examined using ANOVA or Kruskal-Wallis Test. The Mainland-Gart's test will be used for univariate analysis of the primary outcome, when the assumption of no carry-over effect holds. For multivariate analysis, the Generalized Linear Mixed Model will be used to assess the treatment effect, period effect, and treatment-by-period interaction effect, and to adjust for other risk factors such as gender or age. The analysis of survival data will be carried out if such data are available, using the Kaplan-Meier method with log-rank test to compare time-to-event between the two arms and the proportional hazard Cox model to investigate potential prognostic factors. Based on pilot human studies, we anticipate a reduction in the number of ectopic beats during worst 10 second period of exercise from 13 ± 5 beats to 5 ± 5 beats. Assuming an of 0.05 and 80% power, we would need only 5 subjects to show a statistically significant reduction, as this is a paired analysis.
Privacy/Confidentiality Issues
Only individuals directly involved with the study will have access to data. Information is for research purposes only and will be used for publication purposes. All participants will have their names concealed. Access to identified patient information will be limited to the investigators listed within this IRB application. De-identified information with HIPPA identifiers removed will be available to other investigators following appropriate IRB approval. Confidentiality and security will be maintained for the database. The database is stored behind a firewall (in addition to the institutional firewall) with the highest level of protection, i.e. the same level of protection as the on-line hospital information system at Vanderbilt. This means that users must logon to a web server that sits between the institutional firewall and the firewall to the database, and only this application server is allowed to query the database. Only users approved through our institutional review board will be allowed access to patient identifiers. Other levels of authorization may exist for future approved users following IRB approval, e.g. access to de-identified data.
Data is initially collected in the medical record for each individual study participant. The information will be extracted from the patient's medical record and then transferred into the Case Report Form (CRF).
The CRFs will include personal identifiers for participant. However, this data will not be accessible as numbers and initials are assigned for each participant and these will become the identifying information for each study participant. A master list with patient demographics will only be accessible to the principle investigator and his senior coinvestigator. This data will not be available to others. 
A Prospective Randomized Crossover trial of Oral
Background
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a genetic arrhythmia syndrome characterized by frequent ventricular ectopy and polymorphic, classically bidirectional ventricular tachycardia with physical or emotional stress, which also carries a risk of ventricular fibrillation and sudden death, despite no structural heart abnormality. (Liu et al.) The disease is caused by mutations in the cardiac ryanodine receptor gene (RYR2) or cardiac calsequestrin gene (CASQ2). (Priori et al.;Postma et al.) Exercise can elicit ectopy or VT in the majority of CPVT patients. Treatment consists of beta-blockers and/or calcium channel blockers, but up to 30% of patients require implantable cardioverter-defibrillators (ICDs) due to recurrent symptoms on medical therapy (Priori et al.) .
Rationale and Specific Aim
The Specific Aim of this protocol is to test the hypothesis that ventricular ectopy and/or VT on treadmill exercise test in patients with CPVT on standard therapy is reduced by flecainide, but not by placebo.
This will be a single-blind (blinded subjects) randomized cross-over study, in which each patient will receive treatment A (flecainide or placebo), undergo an exercise test, crossover to treatment B (placebo or flecainide) and undergo another exercise treadmill test.
Animal Studies and Previous Human Studies
Recently, we discovered that the class 1C antiarrhythmic agent flecainide directly blocked RyR2 channels, prevented RyR2-mediated premature Ca waves that trigger CPVT in vivo. (Hilliard et al.) Flecainide also appeared to be effective during short-term treatment in two highly symptomatic Based on these animal studies, we have collaborated with international centers to perform am open-label, nonrandomized therapeutic trial of oral flecainide for patients with CPVT and persistent ventricular ectopy on exercise testing on standard therapy. In this trial, 86% of patients had improvement of ventricular ectopy on exercise, and there was no worsening of ectopy with flecainide added to standard therapy.
Inclusion/Exclusion Criteria
• Clinical diagnosis of CPVT, based on: o reproducible polymorphic or bidirectional ventricular tachycardia with exercise OR o Ventricular ectopy on exercise test with RYR2 or CASQ2 mutation • Functioning ICD in place • On stable dose of standard therapy defined as the maximal tolerated dose of betablocker and may include a calcium channel blocker. On stable doses of CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine, bupropion, cimetidine) or inducers (rifampin, carbamazepine, phenytoin, Phenobarbital). If CYP2D6 inhibitor/inducer doses require changes during the course of the subject's treatment with active flecainide, serum flecainide levels will be monitored o Patients on flecainide are also eligible for enrollment after a 1 week "washout" period during which flecainide is discontinued, and standard therapy alone is used.
Exclusion criteria:
• Pregnant females • Children < 5 years of age The treating physicians at each center will identify potential subjects and present a brief overview of the study; if the subject (or his/her parent/legal guardian for patients < 18 years) is interested, an investigator will be contacted and will approach them. Informed consent will be obtained by the investigator after discussing the study in detail, including the voluntary nature of participation and notification the subject can withdraw at any time. Ample time for questions and answers will be allowed. The investigator will give the subject and his/her legal guardian the opportunity to take the consent home to think about it more, with the option to call or meet with the investigator to ask additional questions. If the subject and his/her parent/legal guardian agree to participate, the investigator will ask them to sign a written, informed consent and assent. A copy of the assent and consent will be given to the subject and his/her parent/legal guardian. Subjects who are < 18 years of age at the time of enrollment who turn 18 years of age during the study period will be re-consented after their 18 th birthday. Subjects who wish to participate in the clinical trial without providing a DNA sample will be allowed to do so.
Randomization Procedure: This will be a single-blind placebo-controlled randomized crossover study with 2 treatments: oral flecainide or oral placebo. Each enrolled patient will receive both treatments for at least 3 months, with a 1 week washout period between. The order of treatments will be randomized 1:1 across all centers.
Study Procedures
• Review of data confirming clinical diagnosis of CPVT (recordings of polymorphic VT, exercise tests, genetic tests). Required components include:
Patients previously on flecainide with a serum level > 0.5 mcg/ml will receive a study dose equal to their previous dose. Patients previously on flecainide with a serum level < 0.5 mcg/ml will receive a starting dose equal to their previous dose, with uptitration as below. For all subjects not previously on flecainide, the starting dose will be based on age and weight. Children < 12 years of age will be dosed 3 times per day (every 8 hours) and patients > 12 years of age will be dosed 2 times per day (every 12 hours), based on plasma elimination half-life (Perry et al.) For children < 12 years of age an oral suspension will be used, the starting dose will be 2 mg/kg/day and the maximum dose will be 8 mg/kg/day. For patients > 12 years of age the starting dose will be 100 mg per day (50 mg every 12 hours) and the maximum dose will be 400 mg/day. Study drugs will be prepared and distributed by a central investigational pharmacy; flecainide and placebo will be similar in appearance.
The dose escalation will continue until either:
1. The trough flecainide level is > 0.5 mcg/ml 2. The QRS width is > 120 ms or prolonged by > 50% of the baseline QRS 3. The maximum dose is achieved.
At 3 months, all subjects undergo a repeat exercise test (exercise test A) and a serum sample drawn for a flecainide level. Subjects will then immediately discontinue the Treatment A study drug, and after 1 week of standard therapy alone, start treatment B. Determination of flecainide levels will be done as above. After at least 3 months of treatment B, another exercise test (exercise test B) will be performed. Treatment B study drug will be discontinued at the time of exercise test B, and the subject's participation in the study will be complete.
Patients who receive therapy (shock or anti-tachycardia pacing) from their ICD during the course of their participation in the study will be carefully assessed and the ICD data downloaded. Therapies will be categorized as "appropriate" if delivered for ventricular tachyarrhythmias, or "inappropriate" if delivered for other reasons. In the event of an appropriate ICD therapy, a serum sample will be drawn for a flecainide level. Subjects that have events during treatment A will discontinue treatment A, start the 1 week washout period, and crossover to treatment B. Subjects with events during treatment B will be removed from the study and unblinded. Further treatment will be determined by the treating physician.
The primary endpoint will be reduction in ventricular ectopy at exercise test compared to baseline during treatment with flecainide but not placebo.
Reporting of Adverse Events or Unanticipated Problems involving Risk to Participants or Others
Administration of flecainide is associated with the potential for serious side effects. In our preliminary studies, 8% of CPVT patients were unable to take flecainide due to bradycardia or fatigue and dizziness. Patients who discontinue the study drug (flecainide or placebo) due to side-effects will continue to be followed, with an intent-to-treat analysis. Adverse events related to the administration of flecainide will be reported. All unanticipated problems/events such as breach of confidentiality will be reported.
Serious Adverse Events (SAEs) will have to be reported according to the following special procedure:
Study Withdrawal/Discontinuation
Statistical Considerations Statistical Analysis Plan
Our previous open-label comparison of flecainide to standard therapy showed a 7 beat reduction in number of ectopic beats in worst 10 seconds of exercise test (from 12 ± 5 beats to 5 ± 5 beats).
1
A second study in 12 genotype-negative CPVT patients demonstrated a 6 beat reduction in number of ectopic beats in worst 10 seconds of exercise test (from 12 ± 7 beats to 6 ± 7 beats).
2
A target of 14 enrolled subjects provide adequate statistical power (80% power with an alpha of 0.05) to detect the previously observed differences (6-7) in number of PVC's in worst 10 second period during exercise testing. 3 Graphs of Power (Y-axis) vs observed difference in means (X-axis) are provided below. The 2 panels represent power calculations using different values for the within-group standard deviation (SD). These values are informed from the 2 previous studies in CPVT patients using the same methodology (left, within group SD = 5, observed in reference 1; right within group SD = 7, observed in reference 2). Red lines indicate N=13, and blue lines indicate N=12, allowing for potential subject dropout.
Descriptive statistics, including means, standard deviations, and ranges for continuous variables, as well as percentages and frequencies for categorical variables, will be provided to describe the study sample. Pearson chi-square test or Fisher's exact test will be used to assess the categorical variables. Differences between group means for continuous variables will be examined using ANOVA or Kruskal-Wallis Test. Point estimates along with the corresponding pvalues and 95% confidence intervals will be reported. The adjusted p-values and the corresponding 95% confidence interval will be reported for multivariate analyses. Statistical analysis will be done with R for Windows, version 2.9.2 and SAS 9. 1. Total number of ventricular ectopic beats during entire exercise test (rest, exercise, and recovery) 2. Number of ectopic beats during worst 10 second period of exercise test (rest, exercise, and recovery) 3. Ratio of ectopic to sinus beats during worst 10 second period of exercise test (rest, exercise, and recovery)
Privacy/Confidentiality Issues
The CRFs will include personal identifiers for participant. However, this data will not be accessible as numbers and initials are assigned for each participant and these will become the identifying information for each study participant. A master list with patient demographics will only be accessible to the principle investigator and his senior coinvestigator. This data will not be available to others.
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Summary of changes to protocol:
The reasons for changes to the protocol are reflected in the manuscript Methods:
"The primary endpoint was appropriate ICD therapy, and the secondary endpoint was degree of ventricular arrhythmias induced on exercise testing. Adequate power for the primary endpoint required enrolling 60 subjects. In June 2015, after only 14 of the desired 60 subjects were able to be enrolled, the investigators, with approval from the funding source and the Data and Safety Monitoring Board (DSMB), modified the study protocol to evaluate only the secondary endpoint (ventricular arrhythmias on exercise test). At that point, subjects who had completed the Treatment A exercise test crossed over, without the 18 month treatment duration. Similarly, subjects discontinued Treatment B once the three month exercise test was complete."
The protocols differ in the following sections:
Section 2: Aims 1 and 3 removed. Aim 2 becomes primary aim.
Section 6: Study procedures: Duration of therapy shortened from 18 months to 3 months. Primary endpoint changed from cardiac event to ventricular ectopy at exercise test.
Section 9: Statistical considerations are significantly revised, with original and final statistical plans copied below.
Original Statistical Considerations: Sample Size Estimation and Power Analysis
Statistical Analysis Plan
Descriptive statistics, including means, standard deviations, and ranges for continuous variables, as well as percentages and frequencies for categorical variables, will be provided to describe the study sample. Pearson chi-square test or Fisher's exact test will be used to assess the categorical variables. Differences between group means for continuous variables will be examined using ANOVA or Kruskal-Wallis Test. The Mainland-Gart's test will be used for univariate analysis of the primary outcome, when the assumption of no carry-over effect holds. For multivariate analysis, the Generalized Linear Mixed Model will be used to assess the treatment effect, period effect, and treatment-by-period interaction effect, and to adjust for other risk factors such as gender or age. The analysis of survival data will be carried out if such data are available, using the Kaplan-Meier method with log-rank test to compare time-to-event between the two arms and the proportional hazard Cox model to investigate potential prognostic factors. The alpha-spending function of O'Brien-Fleming will be applied for the interim analysis to maintain an overall significance level at 0.05. Point estimates along with the corresponding pvalues and 95% confidence intervals will be reported. The adjusted p-values and the corresponding 95% confidence interval will be reported for multivariate analyses. Statistical analysis will be done with R for Windows, version 2.9.2 and SAS 9. Quantification of arrhythmias: 1. Total number of ventricular ectopic beats during entire exercise test (rest, exercise, and recovery) 2. Number of ectopic beats during worst 10 second period of exercise test (rest, exercise, and recovery) 3. Ratio of ectopic to sinus beats during worst 10 second period of exercise test (rest, exercise, and recovery)
Based on pilot human studies, we anticipate a reduction in the number of ectopic beats during worst 10 second period of exercise from 13 ± 5 beats to 5 ± 5 beats. Assuming an of 0.05 and 80% power, we would need only 5 subjects to show a statistically significant reduction, as this is a paired analysis.
Final Statistical Analysis Plan
1
2
A target of 14 enrolled subjects provide adequate statistical power (80% power with an alpha of 0.05) to detect the previously observed differences (6-7) in number of PVC's in worst 10 second period during exercise testing. 3 Graphs of Power (Y-axis) vs observed difference in means (X-axis) are provided below. The 2 panels represent power calculations using different values for the within-group standard deviation (SD). These values are informed from the 2 previous studies in CPVT patients using the same methodology (left, within group SD = 5, observed in reference 1; right within group SD = 7, observed in reference 2). Red lines indicate N=13, and blue lines indicate N=12, allowing for potential subject dropout. .61
Data are presented as median and range. VO2 calculated from exercise time on Bruce protocol (n=12 baseline, n=11 placebo, n=12 flecainide) using VO2max (ml/kg/min) = 14.76 -(1.379 × T) + (0.451 × T²) -(0.012 × T³).
